Cara Therapeutics Buy Hold or Sell Recommendation

CARA -- USA Stock  

USD 25.42  1.14  4.70%

Given the investment horizon of 30 days, and your above average risk tolerance our recommendation regarding Cara Therapeutics is 'Strong Buy'. Macroaxis provides Cara Therapeutics buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding CARA positions. The advice algorithm takes into account all of Cara Therapeutics available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from CARA buy-and-hold prospective. Check also Cara Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for muliple equity instruments please use Instant Ratings tool.

Time Horizon

Risk Tolerance

Execute Advice
Sell Cara TherapeuticsBuy Cara Therapeutics
Strong Buy

Hype Condition

Current Valuation

Odds of Distress

Economic Sensitivity

Analyst Consensus

Piotroski F Score

Financial Leverage

For the selected time horizon Cara Therapeutics has a risk adjusted performance of 0.1475, jensen alpha of 0.7586, total risk alpha of (0.07), sortino ratio of 0.3154 and treynor ratio of 2.07
Macroaxis buy, hold, or sell recommendation module can be used to complement current analysts and expert consensus on Cara Therapeutics. Our buy, hold, or sell suggestion engine makes use of analyzes the corporation potential to grow using all fundamental data market data available at the time. To make sure Cara Therapeutics is not overpriced, please confirm all Cara Therapeutics fundamentals including its Cash per Share, Short Ratio and the relationship between EBITDA and Current Ratio . Given that Cara Therapeutics has Price to Earning of (5.53)X, we suggest you validate Cara Therapeutics market performance and probability of bankruptcy to make sure the company can sustain itself in the current economic cycle given your prevailing risk tolerance and investing horizon.

Cara Therapeutics Trading Alerts and Improvement Suggestions

Cara Therapeutics appears to be very risky and stock price may revert if volatility continues
The company reported previous year revenue of 17.85M. Net Loss for the year was (79.21M) with loss before overhead, payroll, taxes, and interest of (62.06M).
Cara Therapeutics currently holds about 134.45M in cash with (31.36M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.38.
Roughly 62.0% of the company shares are held by institutions such as insurance companies

Cara Therapeutics current analysts recommendations

Target Median Price32.50
Target Mean Price31.60
Recommendation Mean1.70
Target High Price35.00
Number Of Analyst Opinions10
Target Low Price24.00

Cara Therapeutics Returns Distribution Density

Mean Return0.83Value At Risk3.88
Potential Upside5.22Standard Deviation3.89
 Return Density 

Institutional Investors

Security TypeSharesValue
Mesirow Financial Investment Management IncCommon Shares33.4 K719 K
Rothschild Investment CorpCommon Shares29.8 K641 K
Exane DerivativesCommon Shares20 K430.1 K
Dorsey Wright AssociatesCommon Shares56612 K
Nisa Investment Advisors LlcCommon Shares50011 K
New Capital Management LpCommon Shares1.00.0
Rho Capital Partners IncCommon Shares3.6 M70 M
Dld Asset Management LpCall Options352.7 K6.9 M

Cara Therapeutics Greeks

Alpha over DOW
Beta against DOW=0.40
Overall volatility
Information ratio =0.17

Cara Therapeutics Volatility Alert

Cara Therapeutics currently demonstrates below average downside deviation of 2.12. It has Information Ratio of 0.17 and Jensen Alpha of 0.76. However, we do advice investors to further question Cara Therapeutics expected returns to make sure all indicators are consistent with the current outlook about its relatively low value at risk.
 Better Than Average     
 Worse Than Average Compare Cara Therapeutics to competition

Cara Therapeutics Fundamental Vs Peers

FundamentalsCara TherapeuticsPeer Average
Return On Equity(84.88)% (0.31)%
Return On Asset(41.49)% (0.14)%
Operating Margin(467.16)% (5.51)%
Current Valuation745.07M16.62B
Shares Owned by Insiders2.87% 10.09%
Shares Owned by Institutions62.37% 39.21%
Number of Shares Shorted6.21M4.71M
Price to Earning(5.53)X28.72X
Price to Book7.75X9.51X
Price to Sales49.97X11.42X
Gross Profit(62.06M)27.38B
Net Income(79.21M)570.98M
Cash and Equivalents134.45M2.7B
Cash per Share3.38X5.01X
Total Debt4.99M5.32B
Debt to Equity4.30% 48.70%
Current Ratio3.40X2.16X
Book Value Per Share2.89X1.93K
Cash Flow from Operations(31.36M)971.22M
Short Ratio6.72X4.00X
Earnings Per Share(2.11)X3.12X
Number of Employees5518.84K
Market Capitalization892.03M19.03B
Total Asset110.9M29.47B
Retained Earnings(79.73M)9.33B
Working Capital103.67M1.48B
Current Asset108.93M9.34B
Current Liabilities5.27M7.9B
   Exercise or conversion by Jeffrey Ives of 2500 shares of Cara Therapeutics subject to Rule 16b-3 [view details]